Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedincellMDCLF +393.00%77 3-Year Revenue Growth Rate is 11.30% as of Mar. 2026, which is 237% above its 10-year median of 3.35. GuruFocus rates MDCLF with a GF Score™ of 77/100 and a GF Value™ of $27.51. The stock has 5 warning signs investors should review. Among 768 Biotechnology companies, Medincell ranks better than 63.67% on this metric.
During the past 12 months, Medincell's average Revenue per Share Growth Rate was -36.90% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 11.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 21.10% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 3.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
During the past 11 years, the highest 3-Year average Revenue per Share Growth Rate of Medincell was 73.90% per year. The lowest was -47.10% per year. And the median was 3.35% per year.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.
Medincell 3-Year Revenue Growth Rate Related Terms
MDCLF vs VRTX, REGN, ALNY: 3-Year Revenue Growth Rate Comparison
For the Biotechnology subindustry, Medincell's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medincell 3-Year Revenue Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medincell's 3-Year Revenue Growth Rate distribution charts can be found below:
* The bar in red indicates where Medincell's 3-Year Revenue Growth Rate falls into.
This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
What does a 3-Year Revenue Growth Rate of 11.30% mean?
Medincell (MDCLF) has a 3-Year Revenue Growth Rate of 11.30% as of Mar. 2026. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for Medincell and its competitors. This is 237% above median its historical median of 3.35. According to the industry distribution chart, Medincell ranks #279 out of 768 companies in the Biotechnology industry, placing it in the top 36.3%.
Is Medincell's 3-Year Revenue Growth Rate too high?
Medincell's current 3-Year Revenue Growth Rate of 11.30% is 237% above median its 10-year median of 3.35. The Biotechnology industry median 3-Year Revenue Growth Rate is 3.05. Medincell's value of 11.30% is 270.5% above this industry median. Based on the distribution chart, Medincell ranks #279 out of 768 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Medincell has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does Medincell's 3-Year Revenue Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medincell ranks #279 out of 768 companies for 3-Year Revenue Growth Rate. This puts Medincell in the upper half of its industry. The industry median 3-Year Revenue Growth Rate is 3.05. Medincell's value of 11.30% is 270.5% above this benchmark. While the company's 10-year median is 3.35 vs. the industry median of 3.05, Medincell has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Revenue Growth Rate for a Biotechnology company?
The median 3-Year Revenue Growth Rate among Biotechnology companies is 3.05, based on 768 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Revenue Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Revenue Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medincell's current 3-Year Revenue Growth Rate of 11.30% is 270.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Revenue Growth Rate mean?
A high 3-Year Revenue Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for Medincell and its competitors. For the Biotechnology industry, the median 3-Year Revenue Growth Rate is 3.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medincell's current 3-Year Revenue Growth Rate is 11.30%, which is 237% above median its own 10-year median of 3.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medincell stock overvalued right now?
Medincell (MDCLF) has a current 3-Year Revenue Growth Rate of 11.30%. The stock's GF Value™ is $27.51, compared to a current price of $34.39 — trading 25% above its estimated fair value. The current 3-Year Revenue Growth Rate is 11.30%, which is 237% above median its 10-year median of 3.35 and 270.5% above the Biotechnology industry median of 3.05. Medincell's overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Revenue Growth Rate calculated?
3-Year Revenue Growth Rate is calculated from a company's financial statements. For Medincell (MDCLF), the current 3-Year Revenue Growth Rate is 11.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medincell (MDCLF) Overvalued in 2026?
Based on GuruFocus' analysis, Medincell stock appears to be overvalued.
The current stock price of $34.39 is trading 25% above its estimated GF Value™ of $27.51.
Key valuation signals for MDCLF:
3-Year Revenue Growth Rate: 11.30% (237% above median its 10-year median of 3.35)
GF Value™: $27.51 vs. price of $34.39 (25% above fair value)
Industry Position: 270.5% above the Biotechnology median (#279 of 768)
No single metric tells the full story. See the MDCLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.
77GF Score
Get the complete analysis for MDCLF
3-Year Revenue Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDCLF has been successfully added to your 
